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Urinary albumin, transferrin and iron excretion in diabetic patients.
The present study was undertaken to determine urinary and serum iron,
transferrin and albumin levels in diabetic patients with varying amounts
of proteinuria. A highly significant correlation was found between
urinary albumin and transferrin excretion over a wide range of urinary
albumin excretion (0.005 to 18 g/g creatinine) (r = 0.972). The urine!
serum ratio of transferrin and albumin were identical, documenting a
similar glomerular leak and tubule handling for these two proteins. In
contrast to the above correlation between transferrin and albumin,
there was no correlation between iron and either of these proteins until
nephrotic range proteinuria had occurred, and even at that time the
correlation was much weaker than that found between the proteins (r =
0.680). Urinary iron excretion increased early in the course of diabetic
renal disease, being increased in 3 of 11 patients without proteinuria and
in 8 of 10 patients with mild proteinuria. All patients with nephrotic
range proteinuria had markedly increased urinary iron excretion (150
166 j.g/g creatinine vs. 6.4 0.7 g/g creatinine in controls) and
decreased serum iron levels (592 189 pg/liter vs. 979 394 pg/liter in
the control group). The iron/transferrin ratio in urine was consistently
greater than the iron/transferrin ratio in plasma at all stages of protein-
uria. In patients with both subnephrotic and nephrotic range protein-
uria, approximately 35 to 40 sg Fe/g creatinine was present in the urine
with an excess of transferrin. In conclusion, urinary iron excretion is
increased early in the course of diabetic renal disease. The fact that iron
is present in the urine in marked excess of transferrin further suggests
that either iron is dissociated from transferrin in the tubule fluid with
transferrin being reabsorbed, or that iron is added to the tubule fluid by
means other than filtration without transferrin. This finding suggests
that iron could be present in tubule fluid in a form which would catalyze
the Haber-Weiss reaction with the formation of free radicals resulting in
tubulointerstitial injury.
Abnormalities of urinary albumin excretion are a hallmark of
diabetic nephropathy, with microalbuminuria serving as a
marker for subsequent development of diabetic nephropathy
with overt proteinuria [1, 2]. Although urinary albumin is the
most commonly measured protein, other proteins are also
excreted in the urine, with some studies showing a change in the
type of proteinuria during the course of diabetic renal disease
[3]. Several studies have shown that increased urinary transfer-
rin excretion may actually precede the development of microal-
buminuna in diabetic patients [4—7]. Since transferrin is the iron
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transporting protein a glomerular leak for transferrin would also
increase tubule fluid and urinary iron. This could result in
increased urinary iron excretion early during the course of
diabetic renal disease. Urinary iron excretion has only been
rarely studied in proteinuric states, and all of these studies have
been directed at renal diseases associated with massive protein-
uria [8—121.
Depending on the state in which iron exists in the urine it
could have the potential to catalyze the Haber-Weiss reaction
with the formation of free hydroxyl radicals [13]. Thus, besides
being another possible marker of glomerular disease, tubule
fluid iron could also play a role in the pathogenesis of tubuloin-
terstitial disease in diabetic nephropathy, as it has been sug-
gested to do in both acute [14] and chronic experimental renal
diseases [11, 12]. The present study was undertaken to define
urinary iron excretion during various phases of diabetic
nephropathy and correlate its excretion with the renal handling
of transferrin.
Methods
Thirty-one adult male patients from the Denver Veterans
Administration Hospital who were diagnosed with adult onset
diabetes participated in this study. Renal function and the
degree of proteinuria were unknown prior to the study. A
random blood and urine sample was obtained from each patient
between the hours of 8 and 12 a.m. Serum and urine samples
were frozen until the time of assay. Patients were divided into
three groups based on the level of urinary albumin excretion
expressed as milligrams of albumin excreted per gram of
excreted creatinine. The values chosen to determine each group
were based on modifications of the upper limit of normal
albumin excretion of 23.4 mg/g of creatinine [4], and a value of
3500 mg/g of creatinine or greater for nephrotic syndrome [15].
Group 1 consisted of 11 patients with urinary albumin excretion
less than 25 mg/g creatinine. Group 2 consisted of 10 patients
with urinary albumin excretion between 25 and 3000 mg/g
creatinine. Group 3 consisted of 10 patients with urinary
albumin excretion greater than 3000 mg/g creatinine. The uri-
nary protein and iron values are expressed per gram of excreted
creatinine. Control values were obtained from members of the
renal division faculty and laboratory staff without diabetes or
renal disease.
Urinary and serum albumin and transferrin were measured by
rate nephelometry with a Beckman Immunochemistry System
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Table 1. Demographic and treatment data
Age years
Group I (N = 11)
Group 2 (N = 10)
61.9 9.3
58.4 8.2
Group 3 (N = 10) 63.0 10.1
Race N (%)
Caucasian 17 (55)
Hispanic 10 (32)
Black 3 (10)
Asian 1 (3)
Sex N (%)
Male 31 (100)
Female 0 (0)
Treatment N (%)
Requiring insulin
Antihypertensive medication
21(68)
20 (65)
II using antibodies from Organon Teknika Inc. (Malvern, Penn-
sylvania, USA). The intra-assay variation (C.V.) was calculated
from human serum and urine samples using triplicate determi-
nations of ten different assays having a normal concentration of
transferrin and albumin. The C.V. for the various samples was
1.07 to 3.93 percent, and the detection limit was 0.1 mg/dl for
transferrin and 0.2 mgldl for albumin. There was no cross
reaction between transferrin and albumin with either antibody
employed in the assays. Serum and urinary iron determinations
were performed with a flameless atomic absorption technique
utilizing a model 5000 Perkin-Elmer atomic absorption spectro-
photometer (Norwalk, Connecticut, USA) equipped with an
automatic sampler and Zeeman background correction [11, 121.
Serum ferritin was determined by the clinical laboratory at the
Denver Veterans Administration Hospital using an immunora-
diometric assay (Quantimune Ferritin IRMA, Bio-Rad, Her-
cules, California, USA). Urine and serum creatinine were
measured with a Beckman creatinine analyzer.
To determine if iron and transferrin were dissociated in the
urine the following calculations and assumptions were made. If
no reabsorption or secretion of iron or transferrin were to occur
then the serum iron/transferrin ratio and the urine iron/transfer-
nfl ratio should be the same. Since these ratio were different,
the following calculations were made:
Serum iron/transferrin = urine calculated iron/transferrin
Solving for urine calculated iron:
Urine calculated iron =
serum iron X urine transferrin/serum transferrin
The calculated urine iron is then compared to the actual
measured urine iron. The same type of calculations can be
performed for urine transferrin.
Statistical analysis was performed using independent groups
t-test, Mann-Whitney U test or analysis of variance where
appropriate. All values are given as mean one standard
deviation. P values less than 0.05 were considered significant.
Results
Demographic data for the patients participating in the study
are shown in Table 1. All patients were males due to the
Veterans Administration Hospital setting of the study. The ages
Variable
Controls
N = 8
Group 1
N = 11
Group 2
N = 10
Group 3
N = 10
Creatinine mg/dI 0.9 0.3 1.2 0.8 2.3 1.2
Iron p.g/Iiter 979 394 1007 441" 740 204 592 189
Albumin gIdI 4.3 0.4c 04d 44 0.4" 3.6 0.4
Transferrin mg/dl 270 58 253 48 280 69 237 41
Ferritin ng/mla 447 441 299 301 139 112
Controls
Variable N = 8
Grou
N = p 111
Grou
N =
p 2
10
Grou
N
p 3
10
45
0.21
25.6
0.21c
150
7.4
166
5.6
12.5 16.9a 468 548
in the three groups were similar. In addition, a similar number
of patients required treatment with insulin and antihypertensive
medication (21 and 20, respectively).
The serum iron, albumin, transferrin and ferritin values for
the groups are shown in Table 2. The serum albumin in group 3
was significantly less than in either group 1 or 2 (P < 0.001). The
serum iron tended to fall in all groups with increasing protein-
uria, with values between group 1 and 3 being significantly
different (P < 0.02). Serum ferritin concentrations tended to fall
with increasing proteinuria but did not achieve statistical sig-
nificance. There was, however, a significant correlation be-
tween serum iron and ferritin (r = 0.596, P < 0.001).
The urinary iron, albumin and transferrin values for the
groups are shown in Table 3. Urinary iron was significantly
higher in group 3 as compared to group 1 (P < 0.03), and in both
group 2 and 3 when compared to control values (P < 0.01).
Urinary iron excretion was greater than the upper limit of
normal for our laboratory (12 ag/g creatinine) in 3 of 11 patients
in group 1, 8 of 10 patients in groups 2 and all patients in group
3.
In all three groups the correlation between urinary albumin
and transferrin excretion were highly significant (r = 0.866, r =
0.905, r = 0.989, P <0.001 for all groups). In the two groups (2
and 3) where values were high enough for meaningful compar-
ison, the urine/plasma ratio for transferrin and albumin and
fractional excretion of these two proteins (Group 2 fractional
excretion albumin = 0.007% and fractional excretion transferrin
= 0.004%, Group 3 fractional excretion albumin = 0.524% and
fractional excretion transferrin 0.465%) were essentially
identical.
In groups I and 2 there was no correlation between urinary
iron excretion and either transferrin or albumin excretion. In
group 3 there was a significant correlation between iron and
transferrin (P < 0.04) and albumin (P < 0.03). Urinary iron/
transferrin ratio in group 2 was 3.4 g iron/mg transferrin and
Table 2. Serum values
a Normal values in the clinical laboratory of the Denver Veterans
Administration Hospital are 16 to 350 ng/ml
b P < 0.05 vs. Group 3
P < 0.01 vs. Group 3
d P < 0.001 vs. Group 3
Table 3. Urine values (expressed per gram of excreted creatinine)
Iron j.g 6.4 2.8a 13 ll
Albumin g 0.005 0.002c 0.01 0.06c
Transferrin mg 2.7 21b 1.7 o.5
a P < 0.01 vs. Group 3
b P < 0.05 vs. Group 3
P < 0.001 vs. Group 3
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0.32 tg iron/mg transferrin in group 3 as compared to 0.26 and
0.25 tg iron/mg transferrin, respectively, in the serum of these
two groups. As determined from the actual urine iron/transfer-
rin ratio and derived urine iron/transferrin ratio from the serum
iron/transferrin ratio, 33 to 42 g iron/gram creatinine was
dissociated from transferrin in each of these two groups. Using
similar calculations, as described in the Methods sections, 158
mg transferrin/g creatinine was reabsorbed in Group 2 while 132
mg transferrin/g creatinine was reabsorbed in Group 3.
Discussion
Historically transferrin has been used as a marker for the
renal handling of albumin because of its similar molecular size
and the fact that initially it could be more accurately measured
than albumin [16]. However, there are dissimilarities between
transferrin and albumin which could cause these two proteins to
be handled differently. Transferrin is globular in configuration
with its axis being 55 by 28 angstroms [17]. In contrast albumin
is spherical with its axis being 36 angstroms. Besides being
somewhat larger, transferrin is less anionic (p1 5.7) than albu-
min (p1 4.9) [18]. Therefore, enhanced albumin clearance in
relation to transferrin clearance would be expected to be more
affected by alteration in charge than size selectivity. This is
supported by animal studies. In two types of experimental renal
disease, nephrotoxic serum nephritis and puromycin induced
nephropathy, fractional excretion of albumin was consistently
greater than transferrin [11, 12]. Proteinuria has been docu-
mented to occur from altered charge selectivity in one of these
models, puromycin induced nephropathy [19]. In contrast frac-
tional excretion of albumin and transferrin have been shown to
be identical in adriamycin induced nephropathy, a model where
proteinuria results from a defect in size selectivity [201. In the
present study fractional excretion of albumin and transferrin
were found to be the same. This would be expected since
proteinuria in diabetic nephropathy has been shown to result
from a disturbance in size selectivity [21]. Alteration in size
selectivity has also been used to explain the increased urinary
transferrin excretion which can occur prior to the onset of
microalbuminuria in diabetic subjects [41. Other investigators
have also reported similar transferrin and albumin clearance in
diabetics with well established albuminuria [5, 61.
Renal iron handling has been less well studied than either
albumin or transferrin handling. Techniques for the measure-
ment of iron less sensitive than those employed in the present
study (requiring manipulation of the urinary samples to concen-
trate the iron for analysis) have yielded normal values ranging
from 3 to 100 .tg/day [81. Normal values found in the present
study (less than 12 g/g creatinine) are consistent with the lower
values reported. Only a limited number of studies have been
carried out in patients with the nephrotic syndrome [9, 10].
Urinary iron excretion has not previously been studied in
patients with low grade proteinuria or in individuals with
diabetic nephropathy. In the present study albuminuria ranged
from 0.005 to 18 g/g creatinine. Patients were subdivided into
three groups based on the amount of albuminuria. Eighteen of
the 20 patients with any increase in urinary albumin excretion
and all the patients with nephrotic range proteinuria had ele-
vated urinary iron levels. Urinary iron correlated with urinary
transferrin levels only in the group of patients with nephrotic
range proteinuria. However, in both the groups with subnephrot-
ic range proteinuria and nephrotic range proteinuria the urine
iron/transferrin ratio was greater than the ratio found in serum.
The urine iron was approximately 35 to 40 p.g/g creatinine in
excess of transferrin in both proteinuric groups. To account for
this amount of dissociated iron in the urine approximately 150
mg of transferrin would have to be reabsorbed. This would
further imply that since a comparable amount of transferrin was
reabsorbed in low and high grade proteinuric states, then
reabsorption is determined by a tubule maximum rather than
the concentration of transferrin present in the tubule fluid.
Additional support for the dissociation of iron from transferrin
is the fact that the mean transferrin level of 12.5 mg (0.156
mol) transferrin/g creatinine in group 2 would maximally bind
only 18 (0.312 .tmol) of the 45 p.g iron/g creatinine in the urine
if both binding sites on transferrin were occupied.
Dissociation of iron from transferrin could have additional
ramifications. Depending on the state in which iron exists, it can
catalyze the Haber-Weiss reaction with the formation of hy-
droxyl radicals. Since these radicals are toxic to virtually all
biological membranes, they could play a role in the pathogen-
esis of the tubulointerstitial disease present in diabetic nephrop-
athy. That tubule injury may occur early during the course of
diabetic renal disease is suggested by the finding of increased
excretion of the tubule enzymes, 1-alpha microglobulin and
beta2-microglobulin during this period [5, 22, 23].
Serum iron levels were found to fall progressively in associ-
ation with increased albuminuria and urinary iron loss. In
addition, serum ferritin levels also tended to decrease with
increasing albuminuria and urinary iron losses. This might
suggest that although urinary iron loss in male patients with the
nephrotic syndrome does not usually result in iron deficiency, it
may reduce iron stores making the individual more at risk of
developing iron deficiency if there are other avenues of iron
loss.
In conclusion, we have observed the following results when
examining urinary albumin, transferrin and iron excretion in
patients with diabetes: (1) urinary iron excretion was above the
upper limit of normal in 21 of 31 diabetic patients and increased
with the degree of proteinuria, (2) urinary albumin and iron and
urinary transferrin and iron are significantly correlated only in
patients with overt proteinuria, (3) iron is dissociated from
transferrin in the urine.
Reprint requests to Randy L. Howard, M.D., Indiana University
School of Medicine, Renal Section, Fesler Hall 108, 1120 South Drive,
Indianapolis, Indiana 46202-5116, USA.
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